Emcure Pharmaceuticals FY26 Revenue Surges 16.6% to ₹9,204 Crore; PAT Jumps 33.1%
Emcure Pharmaceuticals reported FY26 revenue of ₹9,204 crore, up 16.6% YoY. PAT increased 33.1% to ₹941 crore. EBITDA grew 21.8% to ₹1,789 crore with margins at 19.4%. International business showed strong growth, contributing ₹5,177 crore. The company highlighted its robust product pipeline and strategic partnerships.
The significant growth in revenue and profits, coupled with strategic expansion and pipeline development, is expected to have a substantial positive impact on the company's market position and investor confidence.
The company reported strong year-on-year growth in revenue and profits, along with margin expansion and improved ROCE, indicating a positive financial performance.
Emcure Pharmaceuticals Limited announced its financial results for the full year and fourth quarter ending March 31, 2026. The company reported a significant 16.6% year-on-year growth in revenue from operations, reaching ₹9,204 crore for the full year FY26, up from ₹7,896 crore in FY25.
For the fourth quarter of FY26, revenue from operations stood at ₹2,470 crore, a 16.7% increase compared to ₹2,116 crore in Q4 FY25. The company's international business demonstrated robust performance, with a 22.2% YoY growth in FY26, contributing ₹5,177 crore to the total revenue. The European market saw a 25.5% increase, reaching ₹1,850 crore, while Canada's revenue grew by 18.7% to ₹1,487 crore. The Rest of the World (RoW) segment also experienced strong growth of 21.8%, amounting to ₹1,840 crore.
The company's Profit After Tax (PAT) for the full year FY26 surged by 33.1% to ₹941 crore, compared to ₹707 crore in FY25. Adjusted PAT also saw a substantial increase of 40.9% to ₹1,008 crore. EBITDA for the full year rose by 21.8% to ₹1,789 crore, with EBITDA margins improving by 83 bps to 19.4%.
Emcure highlighted key achievements for FY26, including revenue growth above guidance, driven by strong performance in international markets and domestic business growth in line with the IPM. EBITDA margins improved due to productivity enhancements and scaling of in-house products. The company also saw an improvement in ROCE by 180 bps to 23.8%.
The investor presentation also detailed Emcure's robust pipeline of differentiated products across various platforms like Biologics, NDDS, Complex Injectables, and ADCs. Strategic in-licensing partnerships with Sanofi, Novo Nordisk, and Roche, along with acquisitions like Zuventus Healthcare, were emphasized as key growth drivers. The company is expanding into new therapeutic segments such as Consumer and Dermatology, and strengthening its presence in Renal, Oncology, and CNS.
What to do with a filing like this
Emcure Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.